Skip to content

    Lupin

    LUPIN
    Healthcare·8 May 2026
    Management Summary

    Lupin delivered a strong Q4 and full fiscal year FY26, achieving record sales and profitability driven by robust growth across all key geographies, particularly the US and India. The company's strategic focus on complex products, biosimilars, and specialty segments is yielding results, with a significant increase in net cash. However, Q4 saw a sequential EBITDA decline due to one-off settlement costs and higher operating expenses, and the company anticipates a higher effective tax rate in FY27.

    Highlights

    5
    • Total revenue from operations for Q4 FY26 was INR 7,475 crores, marking a 32% YoY growth and the 15th consecutive quarter of growth.

    • EBITDA for Q4 FY26 increased by 68% YoY to INR 2,171 crores, with the margin expanding by 620 basis points to 29.4%.

    • The US business achieved record sales of USD 1.3 billion for the full year FY26, representing an impressive 40% YoY growth, driven by new product launches like Tolvaptan and Mirabegron.

    • India's core prescription business grew 14.5% YoY in Q4 FY26, outperforming IPM growth by 1.3 times, with the chronic segment now accounting for 66% of the portfolio.

    • Net cash position significantly improved to INR 4,636 crores as of March 31, 2026, compared to INR 310 crores last year.

    Concerns

    3
    • Q4 EBITDA declined QoQ despite revenue growth, attributed to increased manpower costs, Astellas settlement for Mirabegron, and foreign exchange impact.

    • Effective Tax Rate (ETR) is expected to increase to 25-26% in FY27 from 22.1% in FY26 due to the phasing out of incentives on domestic facilities.

    • The diabetes segment in India grew 9.4% against a category growth of 12.2%, impacted by the loss of exclusivity for certain in-licensed products.

    Key financials

    Single quarter

    10 metrics
    1. 01Total Revenue from Operations₹7,475 Cr+32%YoY
    2. 02EBITDA₹2,171 Cr+68%YoY
    3. 03EBITDA Margin29.4%+6.2%YoY
    4. 04Gross Margins75%+13.3%YoY
    5. 05R&D Spend₹590 Cr

    Segment breakdown

    Q4 SalesFY26 Sales
    US Business371 Mn1,318 Mn
    India Region1,908 Mn8,114 Mn
    Other Developed Markets845 Mn3,244 Mn
    Emerging Markets991 Mn3,483 Mn
    GIB Business
    Heatmap· 2 shared metrics

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Debt

    Net ₹4,636 crores

    M&A

    VISUfarma

    acquisition · integrated

    Liquidity

    Cash ₹4,636 crores

    Focus on increased cash generation for our business, continue to explore strategic allocation of capital to ensure long term mission of the company including on the specialty front.

    Guidance & targets

    12
    CategoryTargetPriority
    Revenue
    Overall Sales Growth
    high-single digits
    High
    Profitability
    EBITDA Margin
    around 25%
    High
    R&D
    R&D Spend (% of Sales)
    around 8%
    High
    Tax Rate
    Effective Tax Rate (ETR)
    25% - 26%
    High
    India Business
    India Formulations Business Outperformance vs IPM
    1.2x to 1.3x
    High
    India Business
    Chronic Segment Share
    70%
    High
    US Business
    First Biosimilar Launch
    first launch
    High
    US Business
    Product Launches (next 3 years)
    50+ products, 10 exclusive first to files, 4 biosimilars, 2-3 505(b)(2)s
    High
    US Business
    Revenue
    billion dollar plus
    High
    US Business
    Revenue Erosion
    high single digit or low double-digit erosion
    Medium
    US Business
    Respiratory Product Filings
    eight to nine product filings
    High
    VISUfarma
    Top Line Contribution
    comfortably cross USD 100 million
    High

    First US Biosimilar Launch

    Next quarter (Q1 FY27) or H1 FY27
    CurrentExpected in FY27
    TargetSpecific biosimilar launched in US

    Why it matters

    Marks the entry into a key growth area for the US business and validates the complex product strategy.

    This will be strengthened by the launch of our first biosimilars in the year US in FY27.

    How to verify

    guidance_and_targets[metric='US Biosimilar Launches']

    Risks & concerns

    5
    RiskSeverity

    Competition for key US products (Tolvaptan, Mirabegron)

    Anticipated generic competition for Tolvaptan and Mirabegron in FY27 is factored into the 25% EBITDA margin guidance.Management acknowledged

    high

    Increased Effective Tax Rate (ETR)

    ETR expected to rise to 25-26% in FY27 from 22.1% in FY26 due to phasing out of domestic incentives.Management acknowledged

    medium

    Inflationary Pressures on Costs

    Higher ocean (15%) and air (60%) freight costs, raw material price volatility due to Middle East crisis, factored into margin guidance.Management acknowledged

    medium

    India Diabetes Segment Underperformance

    Growth of 9.4% against category 12.2% due to loss of exclusivity for in-licensed products, though offset by other therapy areas.Management acknowledged

    low

    Challenges with Ellipta Product PK

    Difficulty in achieving product PK for Ellipta, making launch challenging, but company continues to work on Breo and Trelegy products.Management acknowledged

    medium

    Q&A highlights

    8

    “Yes, we have factored that in both competition for Mirabegron as well as Tolvaptan.”

    Clarifies the impact of anticipated competition on future profitability guidance, indicating a realistic outlook.

    asked by Tushar Manudhane

    3 min read7 chapters

    Detailed Narrative

    01

    Strong Financial Performance in Q4 and FY26

    Lupin reported its 15th consecutive quarter of year-over-year growth, with Q4 FY26 total revenue from operations reaching INR 7,475 crores, a 32% YoY increase. Full-year FY26 revenue stood at INR 27,958 crores, up 23% YoY. EBITDA for Q4 FY26 was INR 2,171 crores, growing 68% YoY, and the full-year EBITDA reached INR 8,160 crores, a 55% YoY increase, with margins expanding by 590 basis points to 29.7%, surpassing the guidance of 27-28%.

    02

    Robust US Business Growth Driven by New Products

    The US business was a standout, achieving USD 1.3 billion in sales for FY26, an impressive 40% YoY growth. This was primarily driven by new product launches such as Tolvaptan, Mirabegron, and complex injectables like Risperdal Consta® with CGT Exclusivity. The company plans to launch over 50 products in the US over the next three years, including 10 exclusive first-to-files, 4 biosimilars, and 2-3 505(b)(2)s, aiming to sustain its billion-dollar-plus revenue in FY27 despite anticipated competition.

    03

    India Business Outperforms IPM with Strategic Focus

    India's business grew 11.5% YoY in Q4 FY26, with the core prescription segment expanding 14.5%, outperforming the Indian Pharmaceutical Market (IPM) growth by 1.3 times. For the full year, prescription growth was 10.6% against IPM's 9.9%. The chronic segment now constitutes 66% of the portfolio, with a target to reach 70% in the next five years, supported by strong performance in respiratory and cardiac segments.

    04

    Expansion in Emerging and Other Developed Markets

    Emerging Markets delivered an impressive 49% YoY growth in Q4 FY26, led by Brazil, South Africa, and the Philippines, with Brazil growing 113% YoY in local currency due to Dapagliflozin. Other Developed Markets (Europe, Canada, Australia) grew 13.3% YoY in FY26, with European sales exceeding USD 200 million. The acquisition of VISUfarma is expected to further boost presence in Europe and specialty ophthalmology, with a target to cross USD 100 million in top-line contribution within 2-3 years.

    05

    Strategic R&D and Pipeline Development

    R&D spend for FY26 was 7.5% of sales, with a continued focus on complex and specialty platforms, and is expected to be around 8% in FY27. The pipeline includes over 50 active products, with near-term emphasis on respiratory, complex injectables, and biosimilars. The company also highlighted a strong 505(b)(2) pipeline, with product launches anticipated in the next two years, and is strengthening its India Innovation portfolio through both in-house development and in-licensing.

    06

    EBITDA Margin Outlook and Cost Headwinds

    While full-year EBITDA margin was 29.7%, Q4 saw a sequential decline attributed to increased manpower costs, a settlement payment to Astellas for Mirabegron, and foreign exchange impacts. The company has guided for an FY27 EBITDA margin of around 25%, factoring in anticipated competition for Tolvaptan and Mirabegron, as well as increased R&D expenditure. Inflationary pressures, including 15% higher ocean freight and 60% higher air freight, are also being managed and factored into the guidance.

    07

    Improved Net Cash Position and Capital Allocation Strategy

    Lupin's net cash position significantly improved to INR 4,636 crores as of March 31, 2026, compared to INR 310 crores last year. The company emphasized a focus on strategic capital allocation towards specialty assets in Developed Markets, such as the VISUfarma acquisition, and assets that complement or bolster therapy areas in India. This approach aims to deploy capital effectively for long-term growth and mission fulfillment.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.